About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Insulin glargine HOE901
- Company
- Sanofi
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- None currently listed
Efficacy results: Not yet reported
No recruiting studies currently listed
See all studies for this drugData source: ClinicalTrials.gov · trial data as of Sep 11, 2026
Trial details
-
Completed NCT NCT00069784
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
Not yet reported Sanofi 12537 participants Est. completion 2011-12 40 sitesOther conditions: Diabetes Mellitus, Non-Insulin-DependentView official trial listing → -
Completed NCT NCT00941369
Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients
Not yet reported Sanofi 345 participants Est. completion 2012-10 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT00949442
Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment
Not yet reported Sanofi 708 participants Est. completion 2012-07 87 sitesType 2 diabetesView official trial listing → -
Terminated NCT NCT00950534
Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care
Not yet reported Sanofi 25 participants Est. completion 2010-08 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT00965549
Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients
Not yet reported Sanofi 463 participants Est. completion 2012-12 74 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT00993473
6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes
Not yet reported Sanofi 125 participants Est. completion 2011-03 61 sitesOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT01053728
Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)
Not yet reported, Not yet reported Sanofi 46 participants Est. completion 2010-11 1 site Stand-aloneOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT01146678
Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
Not yet reported Sanofi 22 participants Est. completion 2011-01 1 site Added to GLP-1Other conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT01195454
Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®
Not yet reported Sanofi 24 participants Est. completion 2010-12 1 siteOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT01223131
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Not yet reported Sanofi 162 participants Est. completion 2014-03 10 sitesOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT01234597
Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day
Not yet reported Sanofi 219 participants Est. completion 2015-04 11 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01349855
Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
Not yet reported Sanofi 30 participants Est. completion 2011-05 1 site Stand-aloneOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT01461577
Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure
Not yet reported Sanofi 89 participants Est. completion 2012-12 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT01493115
Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Not yet reported Sanofi 18 participants Est. completion 2012-04 1 site Stand-aloneOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT01676233
Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus
Not yet reported Sanofi 20 participants Est. completion 2013-08 1 siteOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT01689129
Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Not yet reported Sanofi 243 participants Est. completion 2014-04 22 sitesOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT01689142
Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus
Not yet reported Sanofi 240 participants Est. completion 2014-06 31 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02058147
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Not yet reported Sanofi 1170 participants Est. completion 2015-06 273 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02058160
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
Not yet reported Sanofi 736 participants Est. completion 2015-07 236 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02200991
Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
Not yet reported Sanofi 136 participants Est. completion 2015-11 20 sites Added to GLP-1Type 2 diabetesView official trial listing → -
Completed NCT NCT02227212
Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM
Not yet reported Sanofi 40 participants Est. completion 2014-11 7 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02273180
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Not yet reported Sanofi 507 participants Est. completion 2016-07 89 sites Stand-aloneOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT02294474
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
Not yet reported Sanofi 505 participants Est. completion 2016-02 103 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02320721
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
Not yet reported Sanofi 1014 participants Est. completion 2016-05 162 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02713477
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
Not yet reported Sanofi 20 participants Est. completion 2016-06 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02752828
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Not yet reported Sanofi 521 participants Est. completion 2018-03-12 113 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03211858
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
Not yet reported Sanofi 597 participants Est. completion 2019-01-12 82 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03285594
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Not yet reported Lexicon Pharmaceuticals 571 participants Est. completion 2019-09-27 106 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03359837
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
Not yet reported Sanofi 384 participants Est. completion 2020-06-29 1 siteType 2 diabetesView official trial listing → -
Terminated NCT NCT03434119
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Not yet reported Sanofi 241 participants Est. completion 2019-01-07 85 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03529123
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
Not yet reported Sanofi 247 participants Est. completion 2019-11-25 13 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03798054
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Not yet reported Sanofi 878 participants Est. completion 2021-03-01 79 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03798080
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Not yet reported Sanofi 426 participants Est. completion 2020-12-01 45 sitesType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07173712
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
Not yet reported Yanbing Li 324 participants Est. completion 2027-12-31Type 2 diabetesView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.